Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin-12

被引:107
作者
Rakhmilevich, AL [1 ]
Janssen, K [1 ]
Turner, J [1 ]
Culp, J [1 ]
Yang, NS [1 ]
机构
[1] GENIVA INC, MADISON, WI 53711 USA
关键词
D O I
10.1089/hum.1997.8.11-1303
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We compared the antitumor effect of several transgene expression plasmids encoding specific cytokines, including interleukin-2 (IL-2), IL-4, IL-6, IL-12, interferon-gamma (IFN-gamma), tumor necrosis factor-alpha (TNF-alpha), and granulocyte-macrophage colony-stimulating factor (GM-CSF), following gene gun-mediated DNA delivery into the epidermis overlying an established intradermal murine tumor, IL-12 gene therapy was much more effective than treatment with any other tested cytokine gene for induction of tumor regression, Strong activation of antitumor immunity in response to IL-12 gene therapy was evidenced by an augmented CD8(+) T cell-mediated cytolitic activity in the draining lymph nodes of tumor-bearing mice, Furthermore, following the IL-12 gene therapy protocol, test mice were able to eradicate not only the treated but also the untreated solid tumors at distant sites, This systemic antitumor effect of IL-12 gene therapy was not associated with visible signs of toxicity or significantly elevated systemic levels of IFN-gamma. These results show that gene gun-mediated in vivo delivery of IL-12 cDNA clearly distinguishes itself from the other cytokine gene therapy approaches tested in parallel, suggesting that this delivery system may be employed as an efficient model for comparative studies of in vivo cytokine gene therapy, The results also suggest that the current IL-12 gene therapy strategy may provide a safer alternative to IL-12 protein therapy for clinical treatment of cancers.
引用
收藏
页码:1303 / 1311
页数:9
相关论文
共 47 条
[21]   CYTOKINE-MEDIATED GENE-THERAPY FOR CANCER [J].
MILLER, AR ;
MCBRIDE, WH ;
HUNT, K ;
ECONOMOU, JS .
ANNALS OF SURGICAL ONCOLOGY, 1994, 1 (05) :436-450
[22]  
MU J, 1995, CANCER RES, V55, P4404
[23]  
MULLEN CA, 1992, CANCER RES, V52, P6020
[24]  
NASTALA CL, 1994, J IMMUNOL, V153, P1697
[25]  
*NIH, 1985, PUBL NIH
[26]   A MOUSE MUTANT P53 PRODUCT RECOGNIZED BY CD4+ AND CD8+ T-CELLS [J].
NOGUCHI, Y ;
CHEN, YT ;
OLD, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (08) :3171-3175
[27]   INFLUENCE OF INTERLEUKIN-12 ON P53 PEPTIDE VACCINATION AGAINST ESTABLISHED METH-A SARCOMA [J].
NOGUCHI, Y ;
RICHARDS, EC ;
CHEN, YT ;
OLD, LJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (06) :2219-2223
[28]  
NORTH RJ, 1984, TRANSPLANT P, V16, P463
[29]  
NORTH RJ, 1985, IMMUNOLOGY, V54, P47
[30]   MECHANISM OF INTERLEUKIN 12-MEDIATED TOXICITIES DURING EXPERIMENTAL VIRAL-INFECTIONS - ROLE OF TUMOR-NECROSIS-FACTOR AND GLUCOCORTICOIDS [J].
ORANGE, JS ;
SALAZARMATHER, TP ;
OPAL, SM ;
SPENCER, RL ;
MILLER, AH ;
MCEWEN, BS ;
BIRON, CA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (03) :901-914